Mikhail Alexandrovich Mashkin

Mikhail Alexandrovich Mashkin

Auto-generated profile, based on publicly available information

Mikhail Alexandrovich Mashkin

Institute for Biomedical Problems of the Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2025 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
AAAlexander Andreev-Andrievsky
Alexander Andreev-Andrievsky
MMM. A. Mashkin
M. A. Mashkin
MVM. Vannous
M. Vannous
OFO. V. Fadeeva
O. V. Fadeeva
YKYu. G. Kazaishvili
Yu. G. Kazaishvili
VSViktoriya Scherbakova
Viktoriya Scherbakova
Today, there is an annualincrease in the prevalence of obesityandoverweightworldwide.Thisproblem is becomingparticularlyrelevant,sincetheseconditionsserve as keyriskfactors for the development of anumber of cardiovascularandmetabolicdisorders,including type 2diabetesmellitus(T2DM).On the territory of the Russian Federation, drugswerepresentedasagonists of glucagon-like peptide of the first type (GLP-1)receptors, the activesubstance of which was producedexclusively by biotechnologicalmeans. It is important to notethat solid-phasechemicalsynthesisisalsooneof the alternativemethods for obtainingGLP-1analogues. A significantadvantage of thismethodoverbiotechnologicalsynthesisis the exclusion of spontaneousamino acid substitutionsand the absence of impuritiescharacteristicofthismethod.The aim. Evaluation of the biological activity of the domestic medicinal product liraglutide (Enligria®, solution for subcutaneous administration, 6 mg/ml, PROMOMED RUS LLC), obtained by chemical synthesis, and a foreign reference drug (Saxenda®,solutionforsubcutaneousadministration,6 mg/ml,NovoNordiskA/C),obtainedbiotechnologically.Materials and methods. The effectiveness of liraglutide preparations was evaluated using a model of induced metabolic syndrome in CBA×C57BL/6 SPF mice (n=36,age6months)according to changes in body weight,feedintake,bloodglucoseandlipid levels, and adiposetissuemass.Results. According to the results of the study, it was shown that Enligria® and Saxenda® drugs have comparable efficacy parameters and statistically significantly (p < 0.05) reduce body weight (13.6±2.1% and 13.3±3.3%, respectively), glucose levels (18 ± 3% and 16 ± 9%), triglycerides (32 ± 12% and 40 ± 18 %) and cholesterol (16 ± 7% and 18 ± 9%) in the blood. Enligria® reduced the mass of structural subcutaneous fat by 32 ± 3% (p < 0.0001), and visceral fat by 34 ± 4% (p < 0.0001). The studiedliraglutidepreparationsshowed a pronouncedhypoglycemiceffect,observedinalldoseranges. The observedhypoglycemiceffectwasdose-dependent.Conclusion. The results of the work indicate the high effectiveness of the synthetic drug Enligria®, which is expressed in reducing body weight and improving metabolic parameters.

1 January 2022 in Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science)
Verified
Journal Article
Closed access
AAAlexander Andreev-Andrievsky
Alexander Andreev-Andrievsky
ELEvgeniia Lagereva
Evgeniia Lagereva
NPNadezda Pankova
Nadezda Pankova
MMM.A. Mashkin
M.A. Mashkin
VMVasiliy N. Manskikh
Vasiliy N. Manskikh
ETE.V. Telyatnikova
E.V. Telyatnikova

22 March 2026 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
AAAlexander Andreev-Andrievsky
Alexander Andreev-Andrievsky
VSViktoriya Scherbakova
Viktoriya Scherbakova
SDS. V. Drugova
S. V. Drugova
MMM. A. Mashkin
M. A. Mashkin
ANA. A. Narizhnyak
A. A. Narizhnyak
KZK. Ya. Zaslavskaya
K. Ya. Zaslavskaya
In the last decade, developed countries have seen a steady increase in the prevalence of metabolic disorders. The most significant among them are obesity and type 2 diabetes mellitus. Tirzepatide is an innovative drug, representing the first-in-class dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Tirzepatide combines the action of two key incretin hormones, providing more comprehensive and effective regulation of glycemia and metabolism compared to traditional GLP-1 monoagonists. Tirzepatide was unavailable in Russia for a long time. However, in 2025, the first domestically produced tirzepatide drug, Tirzetta® (LLC “PROMMOMED RUS”), appeared. The aim. To conduct a comparative evaluation of the efficacy and safety of the reproduced drug Tirzetta® (INN: Tirzepatide, manufacturer LLC “PROMMOMED RUS”) and the reference drug Mounjaro® (INN: Tirzepatide, manufacturer “Eli Lilly”) in a mouse model with induced metabolic syndrome (MS). Materials and methods. The study was conducted on male mice of the C57BL/6 line. To metabolic syndrome (MS) was induced in animals with a diet high in fat and carbohydrates. Three batches of Tirzetta® and one series of Munjaro® were investigated. The drugs were administered at a dosage of 150 µg/kg subcutaneously once every three days for 15 days. During the experiment, glucose tolerance and insulin sensitivity tests were performed. The type of metabolism was determined by indirect calorimetry data. Mice were euthanized on 25th day for humane reasons upon reaching any of the following criteria: body weight loss of more than 15% in a week; serious injuries (fractures, amputations, etc.), appearance of non-healing wounds; seizures; unconscious state. A complete blood count was performed, and the following parameters were determined: glucose, triglycerides, cholesterol, AST, ALT. Necropsy was performed after euthanasia. During necropsy, the thoracic and abdominal organs of the animals were examined, and organs were dissected and weighed. Results. In the MS group animals, body weight increased to 39.5 ± 0.6 g compared to the control group (31.9 ± 0.6 g), representing a 24% increase. Significant hyperglycemia was recorded with a glucose concentration of 14.9 ± 2.7 mmol/L versus 6.1 ± 0.4 mmol/L in the control, as well as a pronounced decrease in glucose tolerance in the loading test. The investigated tirzepatide drugs demonstrated a pronounced hypophagic effect with a 26–28% reduction in body weight, normalization of glycemia with a 48–53% decrease in glucose concentration, and improvement in glucose tolerance and insulin sensitivity. Indirect calorimetry data indicated a decrease in the respiratory exchange ratio, suggesting lipolysis activation. A significant reduction in triglyceride content in blood serum and liver was revealed. The bioequivalence of the investigated drugs Tirzetta® and Mounjaro® was established in the experimental MS model in mice based on a set of therapeutic efficacy and safety indicators. Conclusion . Studies on an experimental model of induced MS in mice showed equivalent efficacy of Tirzetta® (INN: Tirzepatide, manufacturer LLC “PROMMOMED RUS”, Russia) and Mounjaro® (INN: Tirzepatide, manufacturer “Eli Lilly”, USA).

6 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AAAlexander Andreev-Andrievsky
Alexander Andreev-Andrievsky
MMMikhail Alexandrovich Mashkin
Mikhail Alexandrovich Mashkin
SDSofya V. Drugova
Sofya V. Drugova
VSVyacheslav A. Shurshakov
Vyacheslav A. Shurshakov
DPDaniil V. Popov
Daniil V. Popov
BTBion-M 2 Team
Bion-M 2 Team
The combined effects of microgravity and deep-space radiation on whole-body physiology remain poorly quantified for future crewed missions. Bion-M 2, a 30-day high-latitude biosatellite carrying group-housed mice, achieved an ISS-comparable total dose with an enriched galactic cosmic ray fraction, approximating conditions beyond low-Earth orbit. A quantitative atlas of 73 physiological endpoints revealed pronounced antigravity muscle atrophy, immune and gastrointestinal remodeling, and delayed recovery of hematologic and visceral indices through 30 days post-landing. A dry-food–hydrogel diet transformed this response into a stress-dominated, densely interconnected physiological state. Pharmacological Nrf2 activation with omaveloxolone preserved hindlimb muscle mass at ground-control levels and protected visceral organs. These findings establish a systems-level baseline for mammalian adaptation to a deep-space-analog orbit and identify diet and Nrf2 activation as tractable countermeasure levers.